Abbvie – Myelofibrosis – M16 -191
People with Myelofibrosis are asked to participate in a research study being conducted by Monter Cancer Center.
You may be eligible to participate in this study if you:
- Are a male or female at least 18 years of age
- Have adequate bone marrow reserve
- Have adequate renal & hepatic function and enzymes
You may NOT participate in this study if you:
- Subjects must meet all of the criteria in the protocol in order to be included in the study. Anything other than a positive response to the questions in the protocol will result in exclusion from study participation.
Contact Information
Carolyn Pellizzari,Study Coordinator
450 Lakeville Road Lake Success, New York 11042
Email: cpellizzar@northwell.edu
Telephone: (516) 734-8921
Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.
You may be eligible to participate in this study if you:
• Are a male or female at least 18 years of age
• Have a diagnosis of PMF, PPV-MF, or PET-MF
• Have DIPSS risk category of intermediate-1, intermediate-2, or high
• Have been treated with ruxolitinib for ≥ 3 months with a stable dose for at least the last 8 weeks
You may NOT participate in this study if you:
• Have received prior therapy with any drug that inhibits PI3K
• Have recent history of inadequate bone marrow reserve
• Have inadequate liver or renal function
• Have uncontrolled, severe, or unstable cardiac disease
• Have known immunodeficiency virus (HIV) infection
• Have an active bacterial, fungal, parasitic, or viral infection
• Are pregnant or breastfeeding
Contact Information
Hieu Liem Nguyen, Study Coordinator
1300 Morris Park Ave, Ullmann Building Rm 921
Bronx, NY 10461Phone: (718) 325-9392
Email: hinguyen@montefiore.org
Myelofibrosis
People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.
You may be eligible to participate in this study if you:
- Are a man or woman, age 18 years or older
- Have a diagnosis of Myelofibrosis
- Have evidence of inadequate response to ruxolitinib
You may not participate in this study if you:
- Have used any other investigational agent within the past 6 months
- Have a known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
- Have uncontrolled, severe, or unstable cardiac disease
- Are pregnant, breastfeeding or plan to become pregnant
Contact Information
Savita Bhutoria
Study Coordinator
Division of Hematology
921 Ullman,
Albert Einstein College of Medicine
Phone: 718-430-8839
Fax:718-430-8855